Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 6, 1998, Pages 512-514

  De Vos, Dick ^a   Slee, Peter H T J ^b   Briggs, Ray J ^c   Stevenson, Derek ^c  

^a TEVA Pharmachemie   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Loading dose; Serum levels; Steady state; Tamoxifen; Urinary excretion

Indexed keywords

DRUG METABOLITE; TAMOXIFEN; TAMOXIFEN CITRATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; STEADY STATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MIDDLE AGED; TAMOXIFEN;

EID: 0031708067     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050854     Document Type: Article

References (18)

1. Ribeiro GG, Wilkinson PM (1984) A clinical assessment of loading dose tamoxifen for advanced breast carcinoma. Clin Oncol 10: 363
2. Baildam AD, Zaloudik J, Howell A, Barnes DM, Moore M, Sellwood RA (1987) Effect of tamoxifen upon cell DNA analysis by flow cytometry in primary carcinoma of the breast. Br J Cancer 55: 561
3. Osborne RJ, Malik ST, Slevin ML, Harvey VJ, Spona J, Salzer H, Williams CJ (1998) Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule. Br J Cancer 57: 115
4. Spooner D, Fairlamb D, Fermont D (1991) A multicentre trial to compare a loading dose regimen of tamoxifen ("Nolvadex) with conventional dosing in the treatment of advanced breast cancer. The British Tamoxifen Study Group. Clin Oncol 3: 133
5. Buzaid AC, Murren JR, Durivage HJ (1991) High-dose cisplatin with decarbazin and tamoxifen in the treatment of metastatic melanoma [see comments]. Cancer 68: 1238
6. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL (1997) High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 84: 1811
7. Mustacchi G, Milani S, Pluchinotta A, Matteis A de, Rubagotti A, Perrota A (1994) Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: the G.R.E.T.A trial. Group for Research on Endocrine Therapy in the Elderly. Anticancer Res 14: 2197
8. Grill H-J, Trost D, Kreienberg R, Pollow K (1989) Tamoxifen loading dose: determination of the serum level of tamoxifen and 5 metabolites with a new HPLC technique: a randomised trial. Arch Gynecol Obstet 245: 1
9. Fabian C, Sternson L, Barnett M (1980) Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep 64: 765
10. Fabian C, Sternson L, El-Serafi M, Cain L, Hearne E (1981) Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer 48: 846
11. Wilkinson PM, Ribiero GG, Adam HK (1982) Tamoxifen (Nolvadex) therapy-rationale for loading dose followed by maintenance dose for patients with metastatic breast cancer. Cancer Chemother Pharmacol 10: 33
12. Vos D de, Slee PHTJ, Briggs RJ (1992) Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 31: 76
13. Golander Y, Sternson LA (1980) Paired-ion chromatography analysis of tamoxifen and two major metabolites in plasma. J Chromatogr 181: 41
14. Stevenson D, Chapman D, Briggs R, Vos D de (1988) Determination of tamoxifen and five metabolites in plasma and urine. J pharm Biomed Anal 6: 1065
15. Al-Turk WA, Stohs SJ (1983) Kinetics of tamoxifen inhibition of arylcarbon hydroxylase activity of intestinal and hepatic microsomes from male rats. Res Commun Chem Pathol Pharmacol 39: 69
16. Meltzer NM, Stang P, Sternson LA (1984) Influence of tamoxifen and its N-desmethyl and 4-hydroxy metabolites on rat liver microsomal enzymes. Biochem Pharmacol 33: 115
17. Adam HK, Patterson JS, Kemp JV (1980) Studies in the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep 64: 761
18. Slee PHTJ, Vos D de, Chapman D, Stevenson D (1988) The bioavailability of Tamoplex (tamoxifen). 3. A steady-state study in breast cancer patients. Pharm Weekbl [Sci] 10: 22